新辅助化疗对乳腺癌雌激素受体和P53基因及人表皮生长因子受体-2的影响及意义  

Effects of Neoadjuvant Chemotherapy on ER,P53 and HER-2 Expression in Breast Cancer

作　　者：杨海松[1] 黄建军[1] 毛大华[1] 罗轲[1] 

机构地区：[1]贵阳医学院附属医院乳腺外科,贵州省贵阳市550004

出　　处：《中国全科医学》2011年第12期1292-1295,共4页Chinese General Practice

基　　金：贵州省卫生厅基金项目(黔卫发[2007]119号)

摘　　要：目的探讨雌激素受体(ER)和P53基因、人表皮生长因子受体-2(HER-2)在新辅助化疗乳腺癌组织的表达及临床意义。方法采用免疫组织化学方法检测100例乳腺癌患者新辅助化疗前后肿瘤组织中ER、P53基因及HER-2的表达,分析其与疗效的关系。结果新辅助化疗总有效率为79%,新辅助化疗前ER、P53基因阳性表达和阴性表达患者化疗后有效率比较,差异均有统计学意义(P<0.05)。而新辅助化疗前HER-2阳性表达和阴性表达患者化疗后有效率比较,差异无统计学意义(P>0.05)。新辅助化疗前后ER、P53基因和HER-2表达率比较,差异均无统计学意义(P>0.05)。结论新辅助化疗对ER、P53基因及HER-2表达状态无显著影响;ER和P53基因对乳腺癌新辅助化疗疗效有一定预测价值。Objective To explore the expressions of estrogen receptor（ER）,P53 gene and human epidermal growth factor receptor（HER-2） in breast cancer tissues treated by neoadjuvant chemotherapy and their clinical significance.Methods Expressions of ER,P53 and HER-2 were determined by immunohistochemistry in 100 breast cancer（BC） patients before and after neoadjuvant chemotherapy and their relationship to the effect.Results The overall response rate to neoadjuvant chemotherapy was 79%.There was significant difference in chemotherapeutic effect between patients with pre-chemotherapeutic positive and negative expressions of ER,P53 gene after chemotherapy（P0.05）,but not between patients positive and negative expressions of HER-2（P0.05）.No significant difference was noted in expressions of ER,P53 and HER-2 between pre-chemotherapy and post-therapy（P0.05）.Conclusion Neoadjuvant chemo-therapy has not significant influence on expressions of ER,P53 and HER-2.ER and P53 are of some predictive value in effect of neoadjuvant chemotherapy of breast cancer.

关 键 词：乳腺肿瘤 新辅助化疗 抗肿瘤联合化疗方案 基因 P53 

分 类 号：R737.9[医药卫生—肿瘤]